Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
Investing.com - Evercore ISI raised its price target on BridgeBio Pharma stock (NASDAQ:BBIO) to $130 from $125 while maintaining an Outperform rating. The stock currently trades at $67.45, delivering ...
$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial ...
BridgeBio Pharma, Inc.: BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial ...
-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p0.001), which is associated with reduced ACM, further reinforcing its differentiated ...
BridgeBio Pharma Inc. reports first-quarter results Thursday, with investors focused on whether the biotech can sustain the rapid commercial momentum of its flagship drug Attruby while narrowing ...
CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes1 PALO ALTO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: ...
- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001) -Acoramidis mitigated the rise in NT-proBNP through Month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results